相似文献
1
Breast cancer stem cells: we've got them surrounded.
Clin Cancer Res. 2013 Feb 1;19(3):511-3. doi: 10.1158/1078-0432.CCR-12-3450. Epub 2012 Dec 18.
2
Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.
Clin Cancer Res. 2013 Feb 1;19(3):643-56. doi: 10.1158/1078-0432.CCR-12-1063. Epub 2012 Nov 13.
3
Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells.
Breast Cancer Res. 2013;15(4):210. doi: 10.1186/bcr3436.
4
The evaluation of the distribution of CD133, CXCR1 and the tumor associated macrophages in different molecular subtypes of breast cancer.
Histol Histopathol. 2020 Jan;35(1):83-96. doi: 10.14670/HH-18-139. Epub 2019 Jun 28.
5
An updated review on the role of the CXCL8-CXCR1/2 axis in the progression and metastasis of breast cancer.
Mol Biol Rep. 2021 Sep;48(9):6551-6561. doi: 10.1007/s11033-021-06648-8. Epub 2021 Aug 24.
6
Interleukin-8, but not the Related Chemokine CXCL1, Sustains an Autocrine Circuit Necessary for the Properties and Functions of Thyroid Cancer Stem Cells.
Stem Cells. 2017 Jan;35(1):135-146. doi: 10.1002/stem.2492. Epub 2016 Sep 21.
7
A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Breast Cancer Res. 2020 Jan 10;22(1):4. doi: 10.1186/s13058-019-1243-8.
8
An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells.
Cell Death Dis. 2017 Jul 13;8(7):e2932. doi: 10.1038/cddis.2017.319.
9
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.
Theranostics. 2017 Apr 7;7(6):1543-1588. doi: 10.7150/thno.15625. eCollection 2017.
10
The CXCL8-CXCR1/2 pathways in cancer.
Cytokine Growth Factor Rev. 2016 Oct;31:61-71. doi: 10.1016/j.cytogfr.2016.08.002. Epub 2016 Aug 25.
引用本文的文献
1
Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care.
Cancers (Basel). 2024 Mar 14;16(6):1151. doi: 10.3390/cancers16061151.
2
Stem Cell Theory of Cancer: Clinical Implications of Epigenomic versus Genomic Biomarkers in Cancer Care.
Cancers (Basel). 2023 Nov 22;15(23):5533. doi: 10.3390/cancers15235533.
3
Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancer.
J Exp Clin Cancer Res. 2021 Sep 22;40(1):297. doi: 10.1186/s13046-021-02059-6.
4
Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.
Cell Oncol (Dordr). 2019 Dec;42(6):815-828. doi: 10.1007/s13402-019-00464-w. Epub 2019 Aug 2.
5
HER2 in stemness and epithelial-mesenchymal plasticity of breast cancer.
Clin Transl Oncol. 2019 May;21(5):539-555. doi: 10.1007/s12094-018-1961-x. Epub 2018 Oct 10.
6
IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2+ cancer stem cells.
Oncotarget. 2017 Jun 6;8(23):36936-36949. doi: 10.18632/oncotarget.16294.
7
HMGA2 regulates CD44 expression to promote gastric cancer cell motility and sphere formation.
Am J Cancer Res. 2017 Feb 1;7(2):260-274. eCollection 2017.
8
Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer.
Clin Cancer Res. 2016 Sep 1;22(17):4505-16. doi: 10.1158/1078-0432.CCR-15-2956. Epub 2016 Apr 8.
9
Personalised cancer care: promises and challenges of targeted therapy.
J R Soc Med. 2016 Mar;109(3):98-105. doi: 10.1177/0141076816631154. Epub 2016 Mar 1.
10
Identification of stem-like cells and clinical significance of candidate stem cell markers in gastric cancer.
Oncotarget. 2016 Mar 1;7(9):9815-31. doi: 10.18632/oncotarget.6890.
本文引用的文献
1
Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.
Clin Cancer Res. 2013 Feb 1;19(3):643-56. doi: 10.1158/1078-0432.CCR-12-1063. Epub 2012 Nov 13.
2
Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion.
Breast Cancer Res. 2012 Oct 12;14(5):R131. doi: 10.1186/bcr3329.
3
Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population.
Mol Cell. 2012 Aug 24;47(4):570-84. doi: 10.1016/j.molcel.2012.06.014. Epub 2012 Jul 19.
4
Breast cancer stem cells, cytokine networks, and the tumor microenvironment.
J Clin Invest. 2011 Oct;121(10):3804-9. doi: 10.1172/JCI57099. Epub 2011 Oct 3.
5
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts.
J Clin Invest. 2010 Feb;120(2):485-97. doi: 10.1172/JCI39397. Epub 2010 Jan 4.
6
An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation.
Cell. 2009 Nov 13;139(4):693-706. doi: 10.1016/j.cell.2009.10.014. Epub 2009 Oct 29.
7
Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling.
PLoS Biol. 2009 Jun 2;7(6):e1000121. doi: 10.1371/journal.pbio.1000121.
8
Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling.
Int J Radiat Biol. 2009 May;85(5):421-31. doi: 10.1080/09553000902838566.
9
Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab.
Clin Cancer Res. 2009 Mar 15;15(6):2010-21. doi: 10.1158/1078-0432.CCR-08-1327. Epub 2009 Mar 10.
10
HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.
Oncogene. 2008 Oct 16;27(47):6120-30. doi: 10.1038/onc.2008.207. Epub 2008 Jun 30.
Zotero 插件